ArticleFrontiers in public health2025
Quantitative analysis of new drug registration policies for traditional Chinese medicine using the PMC index model.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Empowering chronic disease management with smart healthcare in China: a policy effectiveness evaluation by PMC index model.Frontiers in public health · 2026Article
- Evaluation of China's medical and older adult care integration policy based on the PMC model.Frontiers in public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Traditional Chinese medicine (TCM) culture represents the essence of traditional Chinese culture. The registration of TCM is crucial for promoting its sustainable development and can significantly contribute to the economic growth of the TCM industry. Consequently, the Chinese government has introduced a series of policies regarding TCM registration, aiming to provide scientific and effective guidance for the innovation, inheritance, and development of TCM. At present, China's TCM registration policies are still inadequate, and it is necessary to evaluate and compare them quantitatively. Methods: The present study utilizes text mining methodology and the Policy Modeling Consistency Index (PMC index) model to establish an evaluation system for quantitative assessment and comparison of the Drug Administration Law, Drug Registration Administration Method, Chinese Medicine Registration Administration Method, Chinese Medicine Law, and other relevant legislations spanning from 1985 to 2023. Results: This study revealed that (1) through a comprehensive analysis of high-frequency words, different Traditional Chinese Medicine Regulatory Policies (TCMRPs) shared similar content and objectives, but placed varying degrees of emphasis on specific aspects. (2) The average PMC index of 165 TCMRPs was 5.858, which generally fell within the acceptable range. Among these policies, none achieved perfection, while 39 policies were deemed excellent, constituting 23.6% of the total policies. There were a total of 119 policies falling within the acceptable range, accounting for 72.1% of the total. Additionally, there were 7 policies with below-standard performance, making up for only 4.2% of the total. (3) The PMC index values differed significantly across issuing institutions and incentive methods for various TCMRPs, with generally low scores observed in this regard. However, there were similarities in terms of policy nature, timelines, function, content, mode and scientism rating among these policies. Conclusion: (1) The TCM registration system requires further enhancement and refinement to ensure greater efficiency and compliance with current standards. (2) Technical problems have hindered the research and development of TCM. (3) Talent preservation should be incorporated as a key consideration in the formulation of TCM registration policies. (4) The formulation of TCM registration policies should incorporate economic incentive considerations. (5) China ought to intensify the development of classic and renowned formulas to expedite the registration of novel TCM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.